Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
British Journal of Cancer|March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignanciesShuyang Yao, Filip Janku, Vivek Subbiah, et al.
Oncotarget|October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trialsRabih Said, Yang Ye, Gerald Steven Falchook, et al.
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
NPJ Precision Oncology|January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD AndersonJeong Uk Lim, Heather Y Lin, Lei Kang, et al.
JCO Precision Oncology|October 31, 2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine StudyApostolia-Maria Tsimberidou, David S Hong, Yang Ye, et al.
Scientific Reports|May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiencesShuyang Yao, Funda Meric-Bernstam, David Hong, et al.
JCO Oncology Practice|June 18, 2026
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO GuidelineChristina M Lockwood, Hans J Messersmith, Annette S Kim, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
NPJ Precision Oncology|March 20, 2021
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) studyApostolia Maria Tsimberidou, David S Hong, Siqing Fu, et al.
Pageof 10